国际肿瘤学杂志

国际肿瘤学杂志 ›› 2017, Vol. 44 ›› Issue (5): 383-385.doi: 10.3760/cma.j.issn.1673422X.2017.05.015

• 综述 • 上一篇    下一篇

NVP-BEZ235在肺癌中的研究及应用进展

柴晓宇,许萌,刘新民   

  1. 100034 北京大学第一医院老年科
  • 出版日期:2017-05-08 发布日期:2017-04-19
  • 通讯作者: 刘新民，Email： lxm2128@163.com E-mail:lxm2128@163.com
  • 基金资助:

    国家自然科学基金（81270114）

Research and application of NVPBEZ235 in lung cancer

Chai Xiaoyu, Xu Meng, Liu Xinmin   

  1. Department of Geriatrics, Peking University First Hospital, Beijing 100034, China
  • Online:2017-05-08 Published:2017-04-19
  • Contact: Liu Xinmin E-mail:lxm2128@163.com
  • Supported by:

    National Natural Science Foundation of China (81270114)

PDF

649

摘要： NVP-BEZ235是一种新型磷脂酰肌醇3激酶（PI3K）和哺乳动物雷帕霉素靶蛋白(mTOR)双重抑制剂，已有的研究结果证实NVPBEZ235在肺癌治疗中联合其他药物有着较为理想的效果。对于EGFR突变肺癌亚型、KRAS突变肺癌亚型，NVP-BEZ235的治疗可能有潜在应用价值。

关键词: 肺肿瘤, 突变, NVP-BEZ235

Abstract: NVPBEZ235 is a newly developed dual phosphatidyl linositol kinase 3kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor. Studies have revealed that NVPBEZ235 combinate with other drugs were effective in the treatment of lung cancer. NVPBEZ235 might have a potential application value for the treatment of lung cancer of EGFR mutation subtype and KRAS mutation subtype.

Key words: Lung neoplasms, Mutation, NVP-BEZ235